Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Constellation Brands woke up Thursday to five analyst actions, all pointing down. The most striking was HSBC's Sorabh Daga, who cut the stock from Buy to Hold and slashed the price target 30% to $135 from $192. It is the first outright downgrade in the recent wave, and it arrives after the stock posted a 4.5% earnings gain on October 7.
The post-earnings bounce, it turns out, bought no goodwill on the Street.
HSBC's downgrade is the headline, but four other firms moved simultaneously. Deutsche Bank's Steve Powers kept his Hold but took the target to $127 from $136. Morgan Stanley lowered to $145 from $158 while maintaining Equal-Weight. Needham cut to $150 from $185 on a Buy rating. RBC Capital's Nik Modi trimmed to $182 from $185, keeping Outperform.
The pattern is now a familiar one for STZ. Wells Fargo cut to $140 from $170 on October 5. JP Morgan cut to $133 from $165 in late September. UBS moved to $145 from $168. Citigroup to $165 from $185. Every revision for weeks has gone the same direction.
The consensus mean price target now stands at $152.39. The stock trades at $118.39. That implies roughly 29% upside, but the targets themselves keep compressing toward the share price.
The bull argument rests on brand durability. Modelo and Corona represent more than 90% of revenue. Beer shipments rose 1.8% year on year in the most recent quarter. Management is targeting beer operating margins of 37% to 38% for fiscal 2027 with EPS guidance of $11.20 to $11.90.
The bear argument is structural concentration. Every shipment crosses from Mexico. Tariff risk, slowing category growth, and softening Hispanic consumer confidence are not temporary headwinds. Wine and spirits continue to drag. The EPS momentum factor score sits at the 23rd percentile over 30 days, a weak reading.
The PE stands at 9.8x. That is not an expensive stock. Whether it is cheap depends entirely on whether those earnings estimates have found a floor.
ORTEX Alt Data shows retail attention for Constellation Brands running 3.2 standard deviations above its own 90-day average, based on English Wikipedia views and ORTEX stock page traffic as of October 8. That is attention, not conviction. It reflects the earnings print and the analyst cascade drawing eyes to the name.
Buyback spend in the quarter to April 2026 came to $223.8m, down 27% on the same quarter a year earlier, per SEC EDGAR XBRL data. That is a tangible shift in capital return pace.
The next earnings date is January 7, 2027, 91 days out. The key question before then is whether analyst targets stabilise or continue their descent toward the current share price. A further downgrade to Sell from any firm that currently holds a Buy or Outperform would be a qualitative escalation the market has not yet seen.
Data summary
See the live data behind this article on ORTEX.
Open STZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
